Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2

Wang,Congcong; Zhang,Ruiguo; Tan,Jian; Meng,Zhaowei; Zhang,Yueqian; Li,Ning; Wang,Hanjie; Chang,Jin; Wang,Renfei

doi:10.3892/or.2020.7537

Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2

Authors:
- Congcong Wang
- Ruiguo Zhang
- Jian Tan
- Zhaowei Meng
- Yueqian Zhang
- Ning Li
- Hanjie Wang
- Jin Chang
- Renfei Wang
View Affiliations

Affiliations: Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Institute of Nanobiotechnology, School of Materials Science and Engineering, Tianjin Key Laboratory of Composites and Functional Materials, Tianjin University, Tianjin 300072, P.R. China
Published online on: March 9, 2020 https://doi.org/10.3892/or.2020.7537
Pages: 1491-1502
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumor with a poor prognosis and a low median survival rate because of insufficient effective therapeutic modalities. Recently, mesoporous silica nanoparticles (MSNs) as a green non‑toxic and safe nanomaterial have shown advantages to be a drug carrier and to modify the targeting group to the targeted therapy. To aim of the study was to explore the effects of MSNs co‑loading with 17‑allylamino‑17‑demethoxy‑geldanamycin (17‑AAG; HSP90 inhibitor) and 9‑(6‑aminopyridin‑3‑yl)‑1‑(3‑(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin‑2(1H)‑one (Torin2; mTOR inhibitor) by targeting vascular endothelial growth factor receptor 2 (VEGFR2) on the viability of human anaplastic thyroid carcinoma FRO cells. The cytotoxicity of 17‑AAG and Torin2 were analyzed by MTT assay. The possible synergistic antitumor effects between 17‑AAG and Torin2 were evaluated by CompuSyn software. Flow cytometry was performed to assess the VEGFR2 targeting of (17‑AAG+Torin2)@MSNs‑anti‑VEGFR2 ab and uptake by FRO cells. An ATC xenograft mouse model was established to assess the antitumor effect of (17‑AAG+Torin2)@MSNs‑anti‑VEGFR2 ab in vivo. The results revealed that the combination of 17‑AAG and Torin2 inhibited the growth of FRO cells more effectively compared with single use of these agents. Additionally, the synergistic antitumor effect appeared when concentration ratio of the two drugs was 1:1 along with total drug concentration greater than 0.52 µM. Furthermore, in an ATC animal model, it was revealed that the (17‑AAG+Torin2)@MSNs‑anti‑VEGFR2 ab therapy modality could most effectively prolong the median survival time [39.5 days vs. 33.0 days (non‑targeted) or 27.5 days (control)]. Compared to (17‑AAG+Torin2)@MSNs, the (17‑AAG+Torin2)@MSNs‑anti‑VEGFR2 ab could not only inhibit ATC cell growth but also prolong the median survival time of tumor‑bearing mice in vivo and vitro more effectively, which may provide a new promising therapy for ATC.

View Figures

View References

1	Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, Viola D, et al: Targeted therapy in thyroid cancer: State of the art. Clin Oncol (R Coll Radiol). 29:316–324. 2017. View Article : Google Scholar : PubMed/NCBI
2	Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S, Prolla TA and Chen H: Novel approaches in anaplastic thyroid cancer therapy. Oncologist. 19:1148–1155. 2014. View Article : Google Scholar : PubMed/NCBI
3	Neff RL, Farrar WB, Kloos RT and Burman KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 37:525–538. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zhang R, Zhang Y, Tan J, Wang H, Zhang G, Li N, Meng Z, Zhang F, Chang J and Wang R: Antitumor effect of ¹³¹I-Labeled Anti-VEGFR2 targeted mesoporous silica nanoparticles in anaplastic thyroid cancer. Nanoscale Res Lett. 14:962019. View Article : Google Scholar : PubMed/NCBI
5	Cabanillas ME, Zafereo M, Gunn GB and Ferrarotto R: Anaplastic thyroid carcinoma: Treatment in the age of molecular targeted therapy. J Oncol Pract. 12:511–518. 2016. View Article : Google Scholar : PubMed/NCBI
6	O'Neill JP, Power D, Condron C, Bouchier-Hayes D and Walsh M: Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci. 179:9–15. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sawada M, Oishi T, Komatsu H, Sato S, Chikumi J, Nonaka M, Kudoh A, Osaku D and Harada T: Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer. Int J Clin Oncol. 24:1612–1619. 2019. View Article : Google Scholar : PubMed/NCBI
8	Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UDA: Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
9	Costache MI, Ioana M, Iordache S, Ene D, Costache CA and Săftoiu A: VEGF expression in pancreatic cancer and other malignancies: A review of the literature. Rom J Intern Med. 53:199–208. 2015.PubMed/NCBI
10	Jolly C and Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 92:1564–1572. 2000. View Article : Google Scholar : PubMed/NCBI
11	Porter JR, Fritz CC and Depew KM: Discovery and development of Hsp90 inhibitors: A promising pathway for cancer therapy. Curr Opin Chem Biol. 14:412–420. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
13	Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by modulating beta-Catenin and PI3K/AKT signaling in FRO anaplastic thyroid carcinoma cells. Anticancer Res. 35:5453–5460. 2015.PubMed/NCBI
15	White PT, Subramanian C, Zhu Q, Zhang H, Zhao H, Gallagher R, Timmermann BN, Blagg BS and Cohen MS: Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery. 159:142–151. 2016. View Article : Google Scholar : PubMed/NCBI
16	Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, Uddin S and Al-Kuraya KS: High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis. 35:1564–1572. 2014. View Article : Google Scholar : PubMed/NCBI
17	Beauchamp EM and Platanias LC: The evolution of the TOR pathway and its role in cancer. Oncogene. 32:3923–3932. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tavares C, Eloy C, Melo M, Gaspar da Rocha A, Pestana A, Batista R, Bueno Ferreira L, Rios E, Sobrinho Simões M and Soares P: mTOR pathway in papillary thyroid carcinoma: Different contributions of mTORC1 and mTORC2 complexes for tumor behavior and SLC5A5 mRNA expression. Int J Mol Sci. 19(pii): E14482018. View Article : Google Scholar : PubMed/NCBI
19	Faustino A, Couto JP, Pópulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simões M and Soares P: mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:E1139–E1149. 2012. View Article : Google Scholar : PubMed/NCBI
20	Sidera K and Patsavoudi E: HSP90 inhibitors: Current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 9:1–20. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chen Y, Chen H and Shi J: In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater. 25:3144–3176. 2013. View Article : Google Scholar : PubMed/NCBI
22	Rosenholm JM, Mamaeva V, Sahlgren C and Lindén M: Nanoparticles in targeted cancer therapy: Mesoporous silica nanoparticles entering preclinical development stage. Nanomedicine (Lond). 7:111–120. 2012. View Article : Google Scholar : PubMed/NCBI
23	Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, DeStanchina E, Longo V, Herz E, Iyer S, et al: Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 121:2768–2780. 2011. View Article : Google Scholar : PubMed/NCBI
24	Tang F, Li L and Chen D: Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv Mater. 24:1504–1534. 2012. View Article : Google Scholar : PubMed/NCBI
25	Naz S, Shamoon M, Wang R, Zhang L, Zhou J and Chen J: Advances in therapeutic implications of inorganic drug delivery Nano-platforms for cancer. Int J Mol Sci. 20(pii): E9652019. View Article : Google Scholar : PubMed/NCBI
26	Goel S, Chen F, Hong H, Valdovinos HF, Hernandez R, Shi S, Barnhart TE and Cai: VEGF₁₂₁-conjugated mesoporous silica nanoparticle: A tumor targeted drug delivery system. ACS Appl Mater Interfaces. 6:21677–21685. 2014. View Article : Google Scholar : PubMed/NCBI
27	Tran VA and Lee SW: A prominent anchoring effect on the kinetic control of drug release from mesoporous silica nanoparticles (MSNs). J Colloid Interface Sci. 510:345–356. 2018. View Article : Google Scholar : PubMed/NCBI
28	Ghalhar MG, Akbarzadeh A, Rahmati M, Mellatyar H, Dariushnejad H, Zarghami N and Barkhordari A: Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer. Asian Pac J Cancer Prev. 15:7113–7118. 2014. View Article : Google Scholar : PubMed/NCBI
29	Xu Y, Zhang C, Chen D, Zhao J, Shen Z, Wu Y and Zhu Y: Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: An experimental investigation. Tumour Biol. 34:4065–4071. 2013. View Article : Google Scholar : PubMed/NCBI
30	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
31	Liang C, Wang H, Zhang M, Cheng W, Li Z, Nie J, Liu G, Lian D, Xie Z, Huang L and Zeng X: Self-controlled release of Oxaliplatin prodrug from d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) functionalized mesoporous silica nanoparticles for cancer therapy. J Colloid Interface Sci. 525:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
32	Mortensen JH, Jeppesen M, Pilgaard L, Agger R, Duroux M, Zachar V and Moos T: Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J Drug Deliv. 2013:2092052013. View Article : Google Scholar : PubMed/NCBI
33	Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, Hallanger-Johnson J, McIver B and Eberhardt NL: Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARgamma fusion protein inhibits anaplastic thyroid cancer: A novel therapeutic strategy. Cancer Gene Ther. 20:267–275. 2013. View Article : Google Scholar : PubMed/NCBI
34	Kim H, Kim SW, Seok KH, Hwang CW, Ahn JC, Jin JO and Kang HW: Hypericin-assisted photodynamic therapy against anaplastic thyroid cancer. Photodiagnosis Photodyn Ther. 24:15–21. 2018. View Article : Google Scholar : PubMed/NCBI
35	Hsiao PJ, Lu MY, Chiang FY, Shin SJ, Tai YD and Juo SH: Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol. 195:265–270. 2007. View Article : Google Scholar : PubMed/NCBI
36	Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE and Clark OH: Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 82:3741–3747. 1997. View Article : Google Scholar : PubMed/NCBI
37	Ferrarini M, Heltai S, Zocchi MR and Rugarli C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 51:613–619. 1992. View Article : Google Scholar : PubMed/NCBI
38	Banerji U, Judson I and Workman P: The clinical applications of heat shock protein inhibitors in cancer-present and future. Curr Cancer Drug Targets. 3:385–390. 2003. View Article : Google Scholar : PubMed/NCBI
39	Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M and Ringel MD: 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab. 89:2982–2988. 2004. View Article : Google Scholar : PubMed/NCBI
40	Sato S, Fujita N and Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA. 97:10832–10837. 2000. View Article : Google Scholar : PubMed/NCBI
41	Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, Li Z, Shen M and Kebebew E: Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget. 6:18038–18049. 2015. View Article : Google Scholar : PubMed/NCBI
42	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
43	Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N and Bankovic J: Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 164:411–423. 2014. View Article : Google Scholar : PubMed/NCBI
44	De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, et al: Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 20:400–413. 2011. View Article : Google Scholar : PubMed/NCBI
45	Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS and Farokhzad OC: Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther. 83:761–769. 2008. View Article : Google Scholar : PubMed/NCBI
46	Yang Y and Yu C: Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine. 12:317–332. 2016. View Article : Google Scholar : PubMed/NCBI
47	So Y, Lee YJ, Lee WW and Chung JK: Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene. Oncol Rep. 29:1666–1670. 2013. View Article : Google Scholar : PubMed/NCBI
48	Zhou M, Chen Y, Adachi M, Wen X, Erwin B, Mawlawi O, Lai SY and Li C: Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer. Biomaterials. 57:41–49. 2015. View Article : Google Scholar : PubMed/NCBI
49	Mirzaei-Parsa MJ, Najafabadi MRH, Haeri A, Zahmatkeshan M, Ebrahimi SA, Pazoki-Toroudi H and Adel M: Preparation, characterization, and evaluation of the anticancer activity of Artemether-loaded Nano-Niosomes against breast cancer. Breast Cancer. 27:243–251. 2020. View Article : Google Scholar : PubMed/NCBI